Moderna's gains expand to 120%, hitting a new high since June 2024

Odaily News, according to MSX.COM data, Moderna's gains expanded to 120%, reaching $138.7 per share, marking a new high since June 2024. On the news front, the company, together with Merck, announced that its melanoma skin cancer vaccine met its goals in a large-scale trial. The Nasdaq Biotechnology Index rose 5%, its biggest intraday gain since April 2025.